DANTRIUM (dantrolene sodium) by Pfizer is clinical pharmacology: in isolated nerve-muscle preparation, dantrium has been shown to produce relaxation by affecting the contractile response of the muscle at a site beyond the myoneural junction. First approved in 1979.
Drug data last refreshed 19h ago · AI intelligence enriched 2d ago
Dantrium (dantrolene sodium) is a skeletal muscle relaxant that works by inhibiting calcium release from the sarcoplasmic reticulum, dissociating excitation-contraction coupling. It is approved for acute management and prophylaxis of malignant hyperthermia, a rare but life-threatening pharmacogenetic crisis triggered by certain anesthetics. The drug has also been used off-label for other conditions involving pathologic muscle contractions.
Mature niche product with minimal commercial activity and declining patient claims, indicating a small, specialized team focused on maintenance rather than growth.
CLINICAL PHARMACOLOGY: In isolated nerve-muscle preparation, Dantrium has been shown to produce relaxation by affecting the contractile response of the muscle at a site beyond the myoneural junction. In skeletal muscle, Dantrium dissociates the excitation-contraction coupling, probably by…
Worked on DANTRIUM at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Dantrium offers limited career growth due to its niche, mature market position and approaching loss of exclusivity. Roles are highly specialized and focused on maintaining relationships with anesthesia teams and rare disease specialists rather than driving expansion.